CY1109518T1 - Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης - Google Patents
Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσηςInfo
- Publication number
- CY1109518T1 CY1109518T1 CY20091101110T CY091101110T CY1109518T1 CY 1109518 T1 CY1109518 T1 CY 1109518T1 CY 20091101110 T CY20091101110 T CY 20091101110T CY 091101110 T CY091101110 T CY 091101110T CY 1109518 T1 CY1109518 T1 CY 1109518T1
- Authority
- CY
- Cyprus
- Prior art keywords
- polypeptides
- present
- compositions
- disorders
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
Abstract
Αποκαλύπτονται συνθέσεις και μέθοδοι για διέγερση ή αναστολή αγγειογένεσης και/ή καρδιοαγγείωσης σε θηλαστικά, που περιλαμβάνουν ανθρώπους. Οι φαρμακευτικές συνθέσεις βασίζονται σε πολυπεπτίδια ή σε ανταγωνιστές αυτών που έχουν ταυτοποιηθεί για μία ή περισσότερες από αυτές τις χρήσεις. Οι ανωμαλίες που μπορούν να διαγνωστούν, να αποτραπούν, ή να υποβληθούν σε θεραπευτική αγωγή με τις συνθέσεις της εφεύρεσης περιλαμβάνουν τραύμα όπως πληγές, διαφόρους καρκίνους, και ανωμαλίες των αγγείων που περιλαμβάνουν αθηροσκλήρωση και καρδιακή υπερτροφία. Επιπροσθέτως, η παρούσα εφεύρεση αφορά πρωτότυπα πολυπεπτίδια και μόρια νουκλεϊκών οξέων που κωδικοποιούν αυτά τα πολυπεπτίδια. Επίσης στο παρόν παρέχονται φορείς και κύτταρα-ξενιστές που περιλαμβάνουν αυτές τις αλληλουχίες νουκλεϊκών οξέων, χιμαιρικά πολυπεπτιδικά μόρια που περιλαμβάνουν τα πολυπεπτίδια της παρούσας εφεύρεσης συντηγμένα με ετερόλογες πολυπεπτιδικές αλληλουχίες, αντισώματα που δεσμεύονται με τα πολυπεπτίδια της παρούσας εφεύρεσης και μέθοδοι παραγωγής των πολυπεπτιδίων της παρούσας εφεύρεσης.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/003565 WO2001053486A1 (en) | 1999-03-08 | 2000-02-11 | Compositions and methods for the treatment of tumor |
PCT/US2000/006884 WO2001005972A1 (en) | 1999-07-20 | 2000-03-15 | Compositions and methods for the treatment of immune related diseases |
US25366500P | 2000-11-28 | 2000-11-28 | |
EP00990950A EP1255829B1 (en) | 2000-02-11 | 2000-12-19 | Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109518T1 true CY1109518T1 (el) | 2014-08-13 |
Family
ID=39048807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091101110T CY1109518T1 (el) | 2000-02-11 | 2009-10-26 | Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης |
Country Status (13)
Country | Link |
---|---|
US (2) | US6800604B2 (el) |
EP (1) | EP1255829B1 (el) |
JP (2) | JP2003527844A (el) |
AT (1) | ATE440139T1 (el) |
AU (1) | AU3075701A (el) |
CA (1) | CA2398775A1 (el) |
CY (1) | CY1109518T1 (el) |
DE (1) | DE60042793D1 (el) |
DK (1) | DK1255829T3 (el) |
ES (1) | ES2330918T3 (el) |
IL (2) | IL150987A0 (el) |
PT (1) | PT1255829E (el) |
WO (1) | WO2001059100A2 (el) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030119113A1 (en) * | 1999-07-20 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2499896A1 (en) * | 2002-10-07 | 2004-04-22 | Genentech, Inc. | Hepatocyte growth factor variants |
WO2004104215A2 (en) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7) |
EP1648998B1 (en) | 2003-07-18 | 2014-10-01 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
AU2005244742A1 (en) * | 2004-05-12 | 2005-12-01 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
US9611230B2 (en) | 2004-10-13 | 2017-04-04 | Ptc Therapeutics, Inc. | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
US8759491B2 (en) * | 2009-10-19 | 2014-06-24 | Genentech, Inc. | Modulators of hepatocyte growth factor activator |
US20110206704A1 (en) * | 2009-10-19 | 2011-08-25 | Genentech, Inc. | Methods and compositions for modulating hepatocyte growth factor activator |
US20130149788A1 (en) * | 2011-12-09 | 2013-06-13 | Cornell University | Assay for quantifying elemental sulfur levels in a sample |
US10743996B2 (en) * | 2017-03-24 | 2020-08-18 | Robert L. Bundy | Amnion putty for cartilage repair |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US5382569A (en) | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
ATE312198T1 (de) | 1993-04-05 | 2005-12-15 | Univ Utah Res Found | Diagnose und behandlung von supravalvular aortic stenosis |
US5773223A (en) | 1993-09-02 | 1998-06-30 | Chiron Corporation | Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof |
US5610134A (en) | 1994-04-15 | 1997-03-11 | Genentech, Inc. | Treatment of congestive heart failure |
US5661122A (en) | 1994-04-15 | 1997-08-26 | Genentech, Inc. | Treatment of congestive heart failure |
US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
JP3906314B2 (ja) | 1994-04-25 | 2007-04-18 | ジェネンテク・インコーポレイテッド | カルジオトロフィンおよびその使用 |
US5573762A (en) | 1995-04-24 | 1996-11-12 | Genentech, Inc. | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy |
EP0759467B1 (en) * | 1995-07-24 | 2004-02-11 | Mitsubishi Chemical Corporation | Hepatocyte growth factor activator inhibitor |
WO1997012629A1 (en) * | 1995-10-05 | 1997-04-10 | Genentech, Inc. | Improved angiogenesis using hepatocyte growth factor |
JPH1135480A (ja) * | 1997-07-15 | 1999-02-09 | Mitsubishi Chem Corp | プロテアーゼの活性亢進に起因する疾患の予防及び/または治療剤 |
ES2291198T3 (es) | 1999-07-20 | 2008-03-01 | Genentech, Inc. | Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico. |
-
2000
- 2000-12-19 DE DE60042793T patent/DE60042793D1/de not_active Expired - Lifetime
- 2000-12-19 US US09/742,201 patent/US6800604B2/en not_active Expired - Lifetime
- 2000-12-19 JP JP2001558238A patent/JP2003527844A/ja active Pending
- 2000-12-19 AT AT00990950T patent/ATE440139T1/de active
- 2000-12-19 IL IL15098700A patent/IL150987A0/xx unknown
- 2000-12-19 AU AU30757/01A patent/AU3075701A/en not_active Abandoned
- 2000-12-19 DK DK00990950T patent/DK1255829T3/da active
- 2000-12-19 WO PCT/US2000/034756 patent/WO2001059100A2/en active Application Filing
- 2000-12-19 CA CA002398775A patent/CA2398775A1/en not_active Abandoned
- 2000-12-19 EP EP00990950A patent/EP1255829B1/en not_active Expired - Lifetime
- 2000-12-19 ES ES00990950T patent/ES2330918T3/es not_active Expired - Lifetime
- 2000-12-19 PT PT00990950T patent/PT1255829E/pt unknown
-
2002
- 2002-07-30 IL IL150987A patent/IL150987A/en not_active IP Right Cessation
-
2003
- 2003-12-11 US US10/733,890 patent/US20040132660A1/en not_active Abandoned
-
2009
- 2009-10-26 CY CY20091101110T patent/CY1109518T1/el unknown
-
2012
- 2012-07-19 JP JP2012160868A patent/JP2012246296A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1255829B1 (en) | 2009-08-19 |
JP2012246296A (ja) | 2012-12-13 |
DK1255829T3 (da) | 2009-12-14 |
ES2330918T3 (es) | 2009-12-17 |
PT1255829E (pt) | 2009-11-26 |
IL150987A (en) | 2009-09-01 |
US20020123091A1 (en) | 2002-09-05 |
EP1255829A2 (en) | 2002-11-13 |
IL150987A0 (en) | 2003-02-12 |
WO2001059100A2 (en) | 2001-08-16 |
ATE440139T1 (de) | 2009-09-15 |
US20040132660A1 (en) | 2004-07-08 |
JP2003527844A (ja) | 2003-09-24 |
AU3075701A (en) | 2001-08-20 |
DE60042793D1 (de) | 2009-10-01 |
WO2001059100A3 (en) | 2001-12-20 |
CA2398775A1 (en) | 2001-08-16 |
US6800604B2 (en) | 2004-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109518T1 (el) | Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης | |
ATE458050T1 (de) | Promotion oder inhibition von angiogenese und kardiovaskularisation | |
WO2002008284A3 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
WO2002000690A3 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
WO2000053753A3 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
WO2000053757A3 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
CA2395724A1 (en) | NUCLEIC ACIDS, PROTEINS AND ANTIBODIES | |
CY1112334T1 (el) | Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων | |
WO2001054472A8 (en) | Nucleic acids, proteins, and antibodies | |
WO2003033658A3 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
WO2002018620A3 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
WO2000053752A3 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
WO2001025433A3 (en) | Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization | |
ES2307515T3 (es) | Activacion o inhibicion de la angiogenesis y la cardiovascularizacion. | |
WO2001040464A8 (en) | Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization | |
WO2001055168A8 (en) | Nucleic acids, proteins and antibodies | |
EP1734051A3 (en) | Composition and methods for the diagnosis of tumours | |
WO2001055167A8 (en) | Nucleic acids, proteins, and antibodies | |
WO2001055162A8 (en) | Nucleic acids, proteins, and antibodies |